文献速递头颈外科

携带CTNNA1::ALK重排的腮腺高级别导管内癌:ALK抑制剂治疗期间基因状态变化

High-grade intraductal carcinoma of the parotid gland harboring CTNNA1::ALK rearrangement: Changes in genetic status using genetic testing during treatment with an ALK inhibitor.
PubMed 文献 · Head Neck · 2023-11-29

本文报告一例59岁男性腮腺肿瘤伴颈部淋巴结转移患者,行全腮腺切除及根治性颈清扫,术后放疗后1个月出现多发复发。ALC-TKI阿来替尼初始对携带CTNNA1::ALK重排和TP53突变的导管内癌有效,但10个月后病情恶化并检出PIK3CA突变,患者最终死于多器官衰竭。

要点

  • 携带CTNNA1::ALK重排的腮腺高级别导管内癌对阿来替尼初始有效。
  • 治疗10个月后病情恶化,并检出PIK3CA突变。
  • 临床过程提示TP53和PIK3CA突变同时出现及ALK-TKI药物选择性生长。

核心结论

  • 临床过程提示TP53和PIK3CA突变同时出现以及ALK-TKI药物选择性生长非ALK重排基因肿瘤细胞。

研究设计与样本

  • 病例报告:一例59岁男性腮腺肿瘤伴颈部淋巴结转移患者,接受全腮腺切除及根治性颈清扫。

主要发现

  • 术后放疗完成1个月后患者出现多发复发。
  • 阿来替尼初始对携带CTNNA1::ALK重排和TP53突变的导管内癌有效。
  • 10个月后患者病情恶化,并检出额外PIK3CA突变。
  • 患者最终死于多器官衰竭。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salivary gland carcinomas harboring anaplastic lymphoma kinase (ALK) rearrangements are rare. Here, we present the pathological characteristics, clinical course, and changes in the genetic status of a salivary gland carcinoma harboring a catenin alpha 1 (CTNNA1)::ALK rearrangement during treatment with an ALK tyrosine kinase inhibitor (TKI). METHODS: A 59-year-old man with a parotid tumor and cervical lymph node metastases underwent total parotidectomy and radical neck dissection. One month after completion of postoperative radiotherapy, the patient experienced multiple recurrences. RESULTS: Subsequent treatment with the ALK-TKI alectinib was initially effective against the intraductal carcinoma harboring CTNNA1::ALK rearrangement and TP53 mutation. However, 10 months later the patients' condition deteriorated, and an additional phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation was detected. The patient ultimately succumbed to multiple organ failure. CONCLUSION: The clinical course suggested the concurrent emergence of TP53 and PIK3CA mutations and ALK-TKI drug-selective growth of non-ALK rearrangement gene tumor cells.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Watanabe T, Honma Y, Yonemori K, et al. High-grade intraductal carcinoma of the parotid gland harboring CTNNA1::ALK rearrangement: Changes in genetic status using genetic testing during treatment with an ALK inhibitor. Head Neck. 2023. PMID: 38018800. doi:10.1002/hed.27587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。